Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoPass's Intradermal Delivery Platform Used in Emergex's Next-Generation COVID-19 Vaccination Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopass\u2019s Intradermal Injection Platform Proven to Sustain COVID-19 Vaccine Antibodies Using 1\/15 of The Dose Reports Chinese Institute Of Medical Biology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by NanoPass Technologies

    Menu

    NanoPass Technologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NanoPass Technologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanopass’s Intradermal Injection Platform Proven to Sustain COVID-19 Vaccine Antibodies Using 1/15 of The Dose Reports Chinese Institute Of Medical Biology

              Details:

              The results of IMB’s inactivated SARS-CoV-2 vaccine, have shown that the intradermal 3rd boost allowed for robust and sustained (>6mo) immunogenicity with a favorable safety (no fever and only mild injection site redness and swelling).

              Lead Product(s): Inactivated SARS-CoV-2 Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: YNC Medical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NanoPass Technologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NanoPass's Intradermal Delivery Platform Used in Emergex's Next-Generation COVID-19 Vaccination Study

              Details:

              NanoPass is partnering with Emergex for multiple COVID vaccine LD PepGNP-SARSCoV2, to demonstrate that its drug delivery platform, the MicronJet® 600 can reduce the dose of any vaccine as well as improve immune responses using equivalent doses.

              Lead Product(s): LD PepGNP-SARSCoV2

              Therapeutic Area: Infections and Infectious Diseases Product Name: LD PepGNP-SARSCoV2

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Emergex Vaccines Holding

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY